IDEXX Laboratories to Release 2024 Third Quarter Financial Results
30 Setembro 2024 - 3:00PM
Business Wire
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet
healthcare innovation, has scheduled the release of its 2024 third
quarter results for Thursday, October 31, 2024, before the market
opens. The Company will conduct an analyst conference call
beginning at 8:30 a.m. EDT on that day.
Individuals can access a live webcast of the conference call,
transcript of prepared remarks, and the Q3 2024 Earnings Snapshot
through a link on the IDEXX website, www.idexx.com/investors. An
archived edition of the webcast will be available after 1:00 p.m.
ET on that day via the same link and will remain available for one
year.
The live call also will be accessible by telephone. To listen to
the live conference call, please dial 1-800-289-0462 or
1-323-794-2442 and reference passcode 205740.
About IDEXX Laboratories, Inc.
IDEXX is a global leader in pet healthcare innovation. Our
diagnostic and software products and services create clarity in the
complex, constantly evolving world of veterinary medicine. We
support longer, fuller lives for pets by delivering insights and
solutions that help the veterinary community around the world make
confident decisions—to advance medical care, improve efficiency,
and build thriving practices. Our innovations also help ensure the
safety of milk and water across the world and maintain the health
and well-being of people and livestock. IDEXX Laboratories, Inc. is
a member of the S&P 500® Index. Headquartered in Maine, IDEXX
employs approximately 11,000 people and offers solutions and
products to customers in more than 175 countries and territories.
For more information about IDEXX, visit www.idexx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240930530832/en/
Investor Relations investorrelations@idexx.com
IDEXX Laboratories (NASDAQ:IDXX)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
IDEXX Laboratories (NASDAQ:IDXX)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024